Chemotherapy is one of the main therapeutic option for cancer patients.
However, most anticancer drugs used clinically lack any intrinsic selectivity, causing severe side effects as the result of their toxicity toward healthy tissues.
Therefore, the development of novel therapeutic strategies allowing the selective killing of tumor cells without affecting normal tissues is of great interest to enhance the efficacy of cancer chemotherapies.
With the aim of offering improved treatments to cancer patients, SEEKYO® is designing Smart Molecular Systems (also called therapeutic vectors) programmed for :
- Transport of potent anticancer agents in an innocuous manner toward safe tissues,
- Efficient recognition of malignant specificities
- Controlled release of the parent drug exclusively at the tumor site.
Thanks to our versatile linker technology, we are developing novel Antibody Drug Conjugates (ADC) and Small Molecule Drug Conjugates (SMDC) targeting either cancer cell surface markers (antigen, receptor…) or tumor microenvironment hallmarks.
In vivo strong anticancer activity has been recorded in several animal models for the treatment of various human tumors including :
- Head – neck